FLUZONE QUADRIVALENT 15 MCG / 0.5 ML
HAEMAGGLUTININ-STRAIN B (VICTORIA) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN B (YAMAGATA) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN A (H1N1) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN A (H3N2) : 15 MCG / 0.5 ML · DIN 02420643 · SANOFI PASTEUR LIMITED
Health Canada status: DORMANT
What is FLUZONE QUADRIVALENT?
FLUZONE QUADRIVALENT 15 MCG / 0.5 ML contains HAEMAGGLUTININ-STRAIN B (VICTORIA) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN B (YAMAGATA) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN A (H1N1) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN A (H3N2) : 15 MCG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02420643, held by SANOFI PASTEUR LIMITED, supplied as SUSPENSION for INTRAMUSCULAR administration. Health Canada currently lists it as dormant, status dated 25-Feb-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is FLUZONE QUADRIVALENT used for?
Active immunization against influenza caused by specific strains in the vaccine in adults and children 6 months of age and older.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02420643 |
|---|---|
| Brand name | FLUZONE QUADRIVALENT |
| Generic / active ingredient | HAEMAGGLUTININ-STRAIN B (VICTORIA) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN B (YAMAGATA) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN A (H1N1) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN A (H3N2) : 15 MCG / 0.5 ML |
| Manufacturer | SANOFI PASTEUR LIMITED |
| Strength | 15 MCG / 0.5 ML |
| Dosage form | SUSPENSION |
| Route of administration | INTRAMUSCULAR |
| Schedule | Schedule D |
| ATC code | J07BB02 INFLUENZA, INACTIVATED, SPLIT VIRUS OR SURFACE ANTIGEN |
| AHFS class | 80:12.00 |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 25-Feb-2026 |
| Original market date | 2014-10-15 00:00:00 |
How is it administered?
Administer intramuscularly (deltoid for adults/children >1y; anterolateral thigh for infants <1y). 6-35 months: 0.25 or 0.5 mL; 3-8 years: 0.5 mL; ≥9 years: 0.5 mL. Some children require 2 doses.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 2° to 8°C (35° to 46°F). Do not freeze. (Note: Standard vaccine storage inferred from typical requirements, though section 11 text was truncated in snippet).
How is it supplied?
1 x 5 mL multidose vial; 10 x 0.5 mL single dose prefilled syringes without attached needle.
Contraindications
History of severe allergic reaction to egg protein or any component of the vaccine or after previous administration of the vaccine or a vaccine containing the same components.
Warnings and precautions
Not 100% protective. Postpone in serious acute febrile illness. Risk of GBS within 6 weeks of prior dose. Caution in bleeding disorders. Anaphylaxis equipment must be available.
What can be used instead?
Other Canadian products sharing ATC code J07BB02 INFLUENZA, INACTIVATED, SPLIT VIRUS OR SURFACE ANTIGEN. 8 of 36 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AREPANRIX H5N1 | 3.75 MCG / 0.5 ML | EMULSION | ID BIOMEDICAL CORPORATION OF QUEBEC | MARKETED | DIN 02401886 |
| FLUAD | 15 MCG / 0.5 ML | SUSPENSION | SEQIRUS UK LIMITED | MARKETED | DIN 02362384 |
| FLUCELVAX | 15 MCG / 0.5 ML | SUSPENSION | SEQIRUS UK LIMITED | MARKETED | DIN 02553708 |
| FLUVIRAL | 15 MCG / 0.5 ML | SUSPENSION | ID BIOMEDICAL CORPORATION OF QUEBEC | MARKETED | DIN 02420686 |
| FLUZONE | 15 MCG / 0.5 ML | SUSPENSION | SANOFI PASTEUR LIMITED | MARKETED | DIN 02365936 |
| FLUZONE | 15 MCG / 0.5 ML | SUSPENSION | SANOFI PASTEUR LIMITED | MARKETED | DIN 02365707 |
| FLUZONE HIGH-DOSE | 60 MCG / 0.5 ML | SUSPENSION | SANOFI PASTEUR LIMITED | MARKETED | DIN 02445646 |
| INFLUVAC TETRA | 15 MCG / 0.5 ML | SUSPENSION | BGP PHARMA ULC | MARKETED | DIN 02484854 |
| AFLURIA TETRA | 15 MCG / 0.5 ML | SUSPENSION | SEQIRUS PTY LTD | CANCELLED POST MARKET | DIN 02473283 |
| AFLURIA TETRA | 15 MCG / 0.5 ML | SUSPENSION | SEQIRUS PTY LTD | CANCELLED POST MARKET | DIN 02473313 |
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.